Member Info for martinu

£3m ????

Shychap. A very helpful post, thanks for your views. I started investing (it's really gambling if we're honest, but people wouldn't like to call it that!) a couple of years before the financial crash . And I've been trying to catch up ever since. 😔My nephew tells me it's very hard to pick individual (successful) stocks. It is if they end in "tix". Cheers. MU.

Nick , fair points and Bel a very courteous and friendly suggestion. And to mix your two idioms. Perhaps you could plough your furrow and bury the hatchet therein.

Having said that, it is probably better to do your own research. For me in particular, it is easy to be persuaded by people who have more knowledge of investing and / or business/scientific knowledge than me.

Bk, you would hope so. But Opti struggle to get the HY/FY results out promptly. So I'm not holding my breath. It certainly wouldn't hurt to update on Dr Morepen and Daily Nouri, even if vague in terms of numbers.

Interestingly, both new appointees went to same Uni. COO not over qualified academically. But both have some experience (esp M&A, takeover?). Though not heard of the companies they've worked for. But that's probably down to me . Good luck to both.

It's only taken me most of the day for the penny to drop!

"Year-on-year sales were down slightly in Beauty Actives against a good comparator period BUT were up strongly on a sequential basis compared with the final quarter of 2024."

From a purely statistical point of view, what matters is:

1. Are the results significant? Which we are told they are. The 'p' values being low. Less than 5%.

2. How confident can we be in any claims? This is more pertinent with regard to sample size.

Taking relaxation as an example, let's say the claim is a 12% improvement. ( Not actual figure just for example). With a small sample, this could be say, 12% +/- 9%. With a larger sample this might be 12% +/- 3%. So the margin of error around the %age effect is much greater with smaller samples.

I guess marketing won't go into margins of error!! So they would quote the sample estimate. The 12% in the example above.

Surely wrinkly feet is a job for Zenakine.

SOH has said before that we won't deal with NHS. Also, Opti been doing work with a weight loss clinic. Mentioned in one of the HY/FY announcements.

TW, no idea. Just thought it was interesting. They might tailor opening paras to announcements. But hadn't seen it before March. I hope it is.

... straws but would rather be clutching at sweet fibres.

The opening para of Opti RNSs changed to this recently.

"OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes, provides the following unaudited commercial update for the financial year ended 31 December 2024."

The insertion of "sweet fibres ..." is a new departure.

Loads, thanks

"The Directors of the Company are responsible for this announcement". What's that all about? Is this a non RNS, non Reach RNS? Sorry for my ignorance!

AS, thank you for setting our your thoughts. Very helpful to a non scientific person like me.

Clio, good products, opportunities wasted. Starting to sound like Opti mark 2. But, hope both are listening and learning.

Bel, do you discount Macquarie involvement in depressing SP. Warrants exercised. Forward sold? Are they shorting too?

From LinkedIn

https://www.linkedin.com/company/probiotix-health

Aqua I had missed that. Thanks for highlighting.

Prospector: Horlicks substitute, priceless 😂

With an entry price of 15p, you should make some money. Wish my average was that low. As you may know, many false dawn's over the years. Disappointing revenues, with no real cumulative effect so far.

Some positives emerging. Most notably Dr Morepen. The big game changer would be Sweet. But ...